PROLOR Biotech Inc

PROLOR Biotech — Investor Presentation (December 2012)

17 slides from PROLOR Biotech's investor presentation, Dec 12, 2012

  1. Slide 1: Corporate Presentation Dec 2012

     Corporate Presentation Dec 2012 NYSE Mkt : PBTH

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement  This presentation contains forward - looking statements, including statements regarding the results of current studies and pre - clinical experiments of PROLOR’s long - acting protein programs and are made pursuant to the safe harbour provisions of the Private Securities Liti

  3. Slide 3: PROLOR's Pipeline of Market Leaders

    Indication Product Market Size Preclin. Ph I Ph II Ph III Growth Hormone Disorders hGH – CTP (Adults) $3B hGH – CTP (Children) Hemophilia Factor VIIa - CTP $1.3B 2/ week injection Factor IX - CTP $0.7B 1/week injection Diabetes Type II & Obesity GLP1/Glucagon dual receptor agonist $2B 1/week injecti

  4. Slide 4: CTP: Clinically Validated Technology

    CTP: Clinically Validated Technology  Merck ’s long - acting FSH - CTP (Elonva®) received EU marketing authorization in 2010  Single FSH - CTP injection replaces 7 daily FSH injections in fertility treatment  Two licensees of CTP technology: PROLOR & Merck  Merck holds license for 4 fertility -

  5. Slide 5: hGH-CTP

     hGH - CTP Current Market Size : $ 3 Billion, indicated for children & adults – orphan designation Major Players : Lilly, Roche (Genentech), Pfizer, Novo Nordisk, Merck - Serono Marketed Products : all requiring single daily injections hGH - CTP Value Proposition : Single weekly injection replacing

  6. Slide 6: hGH-CTP Phase II Positive Data - Analysis & Conclusions

     A single weekly injection of hGH - CTP can replace 7 daily injections of commercially available GH  Identified kick - start dosing for Phase III trial  Post - Phase II hGH - CTP Pilot Study Supports two hGH - CTP Injections Per Month  Very Good safety & tolerability profile  Only 50 - 65 % of

  7. Slide 7: hGH-CTP Phase II & III Planning

    hGH - CTP Phase II & III Planning  Pediatric GHD Phase II trial - has initiated and on track  52 - 56 patients,  12 months efficacy & safety  Key outcome: Height velocity  Q 1 2013 filing for adult Phase III trial - program on track  Only 3 months delay compared to original plan  120 - 150 pa

  8. Slide 8: FVIIa-CTP

    FVIIa - CTP  Current Market Size : Hemophilia, Factor VIII non - responders, $ 1.4 Billion, indicated for children & adults – orphan designation Major Players : Novo Nordisk, Baxter, Pfizer, Bayer, CLS Behring Marketed Product : Requires infusion upon bleeding event ( 2 , 3 x per week) Factor VIIa

  9. Slide 9: FVIIa-CTP Has a Profound Survival Effect Compared to NovoSeven Following TVT

    9 FVIIa - CTP has a Profound Survival Effect as Compared to NovoSeven Following TVT 9 20 40 60 80 100 15 min 24 hours % Survival 24 h after TVT TVT in hemophilic mice 40 % 90 %

  10. Slide 10: Reversible-PEGylated MOD-6030 Long-Acting Oxyntomodulin

    Reversible - PEGylated MOD - 6030 Long - Acting Oxyntomodulin  Current Market Size : $ 2 Billion diabetes type II market (GLP - 1 ) + unlimited obesity market Major Players : Roche, Merck, Novo Nordisk, Pfizer, Boehringer Ingelheim , Lilly Native Oxyntomodulin : Natural peptide in the human satiet

  11. Slide 11: MOD-6030 Significant Preclinical Advantages in Weight Reduction

    MOD - 6030 Significant Preclinical Advantages in Weight Reduction 11 Treatment Injection Frequency Dose per Injection Cumulative Dose in 30 Days Cumulative Weight Loss Day 30 (%) Cumulative Food Intake Reduction (%) Formulation Buffer 2x per Day -- -- 0.3% Gain -- OXM 2x per Day 6,000 nm 348,000 nm

  12. Slide 12: Once Weekly MOD-6030 Improves Glycemic and Lipidic Profiles in DIO Mice

    Once Weekly Administration of MOD - 6030 Improves Glycemic and Lipidic Profiles in DIO Mice 12 Terminal Glucose Terminal Cholesterol Terminal Insulin Terminal cholesterol A C E F G 0 50 100 150 200 250 PEG-SH (662 mg/kg) PEG30-EMCS-OXM (6000 nmol/kg) MOD-6030 (6000 nmol/kg) Vehicle (PBS bid) OXM (60

  13. Slide 13: Anticipated Milestones

    Anticipated Milestones 13 Event Timing hGH - CTP: Phase II pediatric study Ongoing hGH - CTP: Phase III adult study regulatory submission (FDA+EMA) Initiate study thereafter in EU, USA Q1 2013 Event Timing MOD - 6030: Further diabetes studies & process, analytical & pharmaceutical development to pre

  14. Slide 14: Intellectual Property

    Intellectual Property  hGH - CTP: 3 patents granted (US, 2009 & 2012 )  CTP Platform patent granted (US, 2011 ) covering hormones, high affinity protein ligands, proteins that induce or regulate an immune response, proteins that are involved with autocrine and paracrine activities, mimetics of the

  15. Slide 15: Leadership

    Leadership OPKO Corporation Shai Novik , MBA President Marian Gorecki , Ph.D. Director Jane Hsiao, Ph.D. , MBA Director Abraham Havron , Ph.D. CEO Phillip Frost, MD. Chairman Steve Rubin, J.D. Director OPKO Corporation 15

  16. Slide 16: Financial Profile

    Financial Profile  NYSE - MKT and TASE listed (PBTH)  $ 40 million cash balance reported September 30 , 2012  63.5 million common shares outstanding, 5.5 million options & 0.3 million warrants  Cash expected to last through 2014 16

  17. Slide 17: Thank You

    Thank You PROLOR BIOTECH Protein.Longevity.Redefined PROLOR BIOTECH

PROLOR Biotech — Investor Presentation (December 2012) on 6ix